Annexin-A1: Therapeutic potential in microvascular disease by Purvis, G, Solito, E, Thiemermann, C

Brutinib has anti‐inflammatory and anti‐diabetic effects in a model of HFD‐ induced insulin resistance and diabetic nephropathy by Purvis, GS, O'Riordan, C, Aranda, H, Bunyard, P, Greaves, DR, Thiemermann, C

Safety and efficacy of artesunate treatment in severely injured patients with traumatic hemorrhage. The TOP-ART randomized clinical trial by Shepherd, JM, Ross, J, Anton, L, Rourke, C, Brentnall, AR, Tarning, J, White, NJ, Thiemermann, C, Brohi, K

Inhibition of IκB Kinase at 24 hours after acute kidney injury improves recovery of renal function and attenuates fibrosis by Johnson, F, Patel, N, Purvis, G, Chiazza, F, Chen, J, Sordi, R, Hache, G, Merezhko, V, Collino, M, Yaqoob, M, Thiemermann, C

RvE1 attenuates polymicrobial sepsis-induced cardiac dysfunction and enhances bacterial clearance by Chen, J, Purvis, GSD, Collotta, D, Al Zoubi, S, Sugimoto, MA, Cacace, A, Martin, L, Colas, RA, Collino, M, Dalli, J, Thiemermann, C

Bruton's tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice by O'Riordan, CE, Purvis, GSD, Collotta, D, Chiazza, F, Wissuwa, B, Al Zoubi, S, Stiehler, L, Martin, L, Coldewey, SM, Collino, M, Thiemermann, C

Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes by Purvis, G, Chiazza, F, Chen, J, Azevedo-Loiola, R, Martin, L, Kusters, D, Reutelingsperger, C, Fountoulakis, N, Gnudi, L, Yaqoob, M, Collino, M, Thiemermann, C, Solito, E

X-linked immunodeficient mice with no functional Bruton's tyrosine kinase are protected from sepsis-induced multiple organ failure by O'Riordan, CE, Purvis, GSD, Collotta, D, Krieg, N, Wissuwa, B, Sheikh, MH, Ferreira Alves, G, Mohammad, S, Callender, LA, Coldewey, SM, Collino, M, Greaves, DR, Thiemermann, C

Inhibition of Bruton's tyrosine kinase regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation by Purvis, GSD, Collino, M, Aranda-Tavio, H, Chiazza, F, O'Riordan, CE, Zeboudj, L, Mohammad, S, Collotta, D, Verta, R, Guisot, NES, Bunyard, P, Yaqoob, MM, Greaves, DR, Thiemermann, C

Novel synthetic, host-defense peptide protects against organ injury/dysfunction in a rat model of severe hemorrhagic shock by Yamada, N, Martin, L, Zechendorf, E, Purvis, G, Chiazza, F, Varrone, B, Collino, M, Shepherd, J, Heinbockel, L, Gutsmann, T, Correa, W, Brandenburg, K, Marx, G, Schuerholz, T, Brohi, K, Thiemermann, C

Identification of Annexina1 as an endogenous regulator of RhoA, and its role in the pathophysiology and experimental therapy of type-2 diabetes by Purvis, G, Collino, M, Loiola, R, Baragetti, A, Chiazza, F, Brovelli, M, Sheikh, M, Collotta, D, Cento, A, Mastrocola, R, Aragno, M, Cutrin, J, Reutelingsperger, C, Grigore, L, Catapano, A, Yaqoob, M, Norata, G, Solito, E, Thiemermann, C

A synthetic peptide designed to neutralize lipopolysaccharides attenuates metaflammation and diet-induced metabolic derangements in mice by Mohammad, S, Al Zoubi, S, Collotta, D, Krieg, N, Wissuwa, B, Ferreira Alves, G, Purvis, GSD, Norata, GD, Baragetti, A, Catapano, AL, Solito, E, Zechendorf, E, Schürholz, T, Correa-Vargas, W, Brandenburg, K, Coldewey, SM, Collino, M, Yaqoob, MM, Martin, L, Thiemermann, C

Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues by Sheikh, MH, Errede, M, d'Amati, A, Khan, NQ, Fanti, S, Loiola, RA, McArthur, S, Purvis, GSD, O'Riordan, CE, Ferorelli, D, Dell'Erba, A, Kieswich, J, Reutelingsperger, C, Maiorano, E, Yaqoob, M, Thiemermann, C, Baragetti, A, Catapano, AL, Norata, GD, Marelli-Berg, F, Virgintino, D, Solito, E